Caldolor

Caldolor is a brand name of ibuprofen, approved by the FDA in the following formulation(s):

CALDOLOR (ibuprofen - solution; intravenous)

• 
  Manufacturer: CUMBERLAND PHARMS
  
  Approval date: June 11, 2009
  
  Strength(s): 400MG/4ML (100MG/ML), 800MG/8ML (100MG/ML) ^[RLD]

Has a generic version of Caldolor been approved?

No. There is currently no therapeutically equivalent version of Caldolor available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Caldolor. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid
  Patent 6,727,286
  Issued: April 27, 2004
  Inventor(s): Leo; Pavliv
  Assignee(s): Cumberland Pharmaceuticals Inc.
  The present invention provides a pharmaceutical composition comprising an aqueous solution of arginine and ibuprofen, wherein the molar ratio of arginine to ibuprofen is less than 1:1, as well as a method of making the same. The present invention also provides a method of treating a condition chosen from pain, inflammation, fever, and/or other conditions alleviated by ibuprofen comprising administering a pharmaceutical composition comprising an aqueous solution of arginine and ibuprofen, wherein the molar ratio of arginine to ibuprofen is less than 1:1.
  
  Patent expiration dates:
  
  
  • November 27, 2021
    
    ✓ 
    Patent use: MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • June 11, 2012 - NEW PRODUCT
  
  

See also...

• Caldolor Consumer Information (Drugs.com)
• Caldolor Injection Consumer Information (Wolters Kluwer)
• Caldolor Advanced Consumer Information (Micromedex)
• Ibuprofen Consumer Information (Drugs.com)
• Ibuprofen Consumer Information (Wolters Kluwer)
• Ibuprofen Capsules Consumer Information (Wolters Kluwer)
• Ibuprofen Chewable Tablets Consumer Information (Wolters Kluwer)
• Ibuprofen Drops Consumer Information (Wolters Kluwer)
• Ibuprofen Injection Consumer Information (Wolters Kluwer)
• Ibuprofen Suspension Consumer Information (Wolters Kluwer)
• Children's Ibuprofen Berry Consumer Information (Cerner Multum)
• Ibuprofen Consumer Information (Cerner Multum)
• Bufen Advanced Consumer Information (Micromedex)
• Equate Children's Ibuprofen - Berry - Dye Free Advanced Consumer Information (Micromedex)
• I-Prin Advanced Consumer Information (Micromedex)
• Midol Advanced Consumer Information (Micromedex)
• Proprinal Advanced Consumer Information (Micromedex)
• Teddy's Choice Children's Ibuprofen - Berry Advanced Consumer Information (Micromedex)
• Teddy's Choice Children's Ibuprofen - Bubble Gum Advanced Consumer Information (Micromedex)
• Teddy's Choice Children's Ibuprofen - Grape Advanced Consumer Information (Micromedex)
• Ibuprofen Advanced Consumer Information (Micromedex)
• Ibuprofen Intravenous Advanced Consumer Information (Micromedex)
• Ibuprofen lysine Intravenous Advanced Consumer Information (Micromedex)
• Ibuprofen AHFS DI Monographs (ASHP)